Title-effectiveness and safety of Danshen injection for acute kidney injury in primary nephrotic syndrome.

OBJECTIVE: To assess the clinical effectiveness and safety of Danshen injection following immunosuppressive therapy in primary nephrotic syndrome (PNS) with acute kidney injury (AKI) patients. METHODS: PNS with AKI patients selected from nephrotic syndrome inpatients between 2012 and 2022 were divided into two groups according to the treatment regimen: the DS group who were treated with the Danshen injection and the SC group who received supportive care. Propensity score matching was used to balance the confounding factors between the two groups. The outcomes were complete and partial renal function recovery for effectiveness analysis and severe bleeding events for safety analysis. Kaplan-Meier curves and log-rank tests were used to compare cumulative recovery rates. Outcome risks were assessed using Cox proportional hazard regression models. RESULTS: 0.006) at 6 months. CONCLUSION: ) in these patients.